"For advanced, compassionate cancer care, patients and their families have trusted St. Luke's Cancer Institute for more than 50 years. Today we're a network of five cancer centers dedicated to state-of-the-art treatment close to home; patient-centered care; cutting-edge research; community education, and early detection. Our cancer center in Twin Falls brings you medical and radiation oncology specialists, access to the best surgeons in the region, onsite pharmacy and lab, and a wide range of support services to care for your overall well-being. We'll be with you and your family every step of the way during your cancer journey, treating cancer, easing symptoms and side effects, and strengthening you physically, mentally, and emotionally."

During the past decade, Saint Luke's Cancer Institute - Twin Falls conducted 172 clinical trials. In the 10-year time frame, 172 clinical trials started and 73 clinical trials were completed, i.e. on average, 42.4% percent of trials that started reached the finish line to date. In the past 5 years, 72 clinical trials started and 61 clinical trials were completed. i.e. 84.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Luke's Cancer Institute - Twin Falls" #1 sponsor was "National Cancer Institute (NCI)" with 103 trials, followed by "SWOG Cancer Research Network" with 40 trials sponsored, "Alliance for Clinical Trials in Oncology" with 33 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 17 trials sponsored and "NRG Oncology" with 17 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Luke's Cancer Institute - Twin Falls" #1 collaborator was "National Cancer Institute (NCI)" with 116 trials as a collaborator, "NRG Oncology" with 23 trials as a collaborator, "Canadian Cancer Trials Group" with 11 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Saint Luke's Cancer Institute - Twin Falls" are "Stage IV Lung Cancer AJCC v8" (11 trials), "Breast Cancer" (9 trials), "Invasive Breast Carcinoma" (8 trials), "Recurrent Lung Non-Small Cell Carcinoma" (8 trials) and "Recurrent Squamous Cell Lung Carcinoma" (8 trials). Many other conditions were trialed in "Saint Luke's Cancer Institute - Twin Falls" in a lesser frequency.

Most popular intervention types in "Saint Luke's Cancer Institute - Twin Falls" are "Drug" (176 trials), "Other" (129 trials), "Biological" (95 trials), "Procedure" (65 trials) and "Radiation" (37 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (59 trials), "Laboratory Biomarker Analysis" (55 trials), "Questionnaire Administration" (42 trials), "Computed Tomography" (38 trials) and "Biospecimen Collection" (35 trials). Other intervention names were less common.

The vast majority of trials in "Saint Luke's Cancer Institute - Twin Falls" are 183 trials for "All" genders, 34 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Luke's Cancer Institute - Twin Falls". undefined are not yet recruiting, 65 are recruiting, 109 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Saint Luke's Cancer Institute - Twin Falls, 6 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Luke's Cancer Institute - Twin Falls, 5 "Phase 1" clinical trials were conducted, 109 "Phase 2" clinical trials and 120 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".